# Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline

> **Open Intelligence Dossier** · First detected: 2026-09-03 17:07 UTC · Category: Business

## Executive Summary
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.


Outlets currently covering the story include MarketBeat, finance.yahoo.com, STAT and Fierce Biotech. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Yahoo Finance | RARE Stock Heads For Record Low: Angelman Trial Miss Leads To Wall Street Downgrades – This Analyst Sees Another Problem Ahead | [Source Link](https://news.google.com/rss/articles/CBMilwFBVV95cUxNdl9jU2VsZ2xpU19SNDV0RDRmY1VSNlNJWk1PMEtkNWhOWV92ZjRLOWxrTHpnQVRYMWZ6cDBBN19rRTdGb1NHbG05OEVsVnkxcnc0LThpMndCOVdMcDExYUNoVWJ2RjZnSl9MWmV6Z09GbFJYWW9ZdXFIMTM1Zng3WXpDVjBPbFdvS0U3WWw5Mm5XaEdKUE9z?oc=5) |
| The Business Journals | Ultragenyx vows 'significant' cuts after experimental rare-disease drug flunks late-stage clinical trial | [Source Link](https://news.google.com/rss/articles/CBMipgFBVV95cUxPRmVIc3ZENmNJTnJCTDVnbmYyNjdxYmRyMUVTZHdnQXBacVZmRm1IMTZtOFpiakpNYUpzazZoWXJ6dDE2VW91ZTZVRzI4VzIwcnBDd21henVtakt1TF8tVGEyNmxEbmRYRkVXblRYYWV4bWVVQzhYcnNpYXpobjRvTzZzLUcwUW1nWkdQLTB2OWgyNUZ0NlV5eFZST29LcTU0bFBuNXZR?oc=5) |
| Yahoo Finance | Why Did RARE Stock Slump 46% After-Hours? | [Source Link](https://news.google.com/rss/articles/CBMikwFBVV95cUxNeElWR3c1Z3pFNDRENEdMR3RWcENaMlh0alNsSks2UlZGNlZLWFN1cGJFUXo3bWJmMUZZaXB3al9GY0NhWUdfejA4UUtrV0pYQ2VzR2pydlFHSTVfeklKR3pWWEw2VGk0UmJWZ3Z0SmJyaDdKdzBsV2NJYzFNZzFQcEQ2aU5iODFCWkc1WHVPbnIwRXM?oc=5) |
| STAT | Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial | [Source Link](https://news.google.com/rss/articles/CBMijgFBVV95cUxOSDJteEt5OEFKQVRJYzFlelJDclhYZHVNNFdhUGlLNW5WdndhemxBVGcxRnpzN01fUm5POHFHQmoyQ2FfWGw5Q0tWSHlKbmFlOVhCd1pScW92dF9GSG5DNDB6dDhYVjVfdHF2bGt6dHBqX3hOQ3dCeVZZU3ZHeFRrUW9ObjVfaU5FSXBRWThn?oc=5) |
| BioPharma Dive | Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study | [Source Link](https://news.google.com/rss/articles/CBMimgFBVV95cUxQQ3JpRG5UM1o5aUNtRHlaYnpQOWdXUUhJdW5DT2g4ZVZvMld3OS16dzNVenNzQnpZN194bUg3d0ZHa0hMRkpaRWJoZU5kVk5QeDgyc2YzLWt3Z1pYZGNreWtsLWdFZGJkakhLbF9adW9ubTdCcVR3cmR1RU1vREpVMXJJN2VHX09kTHlPdGNIV3pqc0poclZqbHJn?oc=5) |
| pharmaphorum | Ultragenyx to slash costs after Angelman trial failure | [Source Link](https://news.google.com/rss/articles/CBMiiAFBVV95cUxPWEEwVEpnQTBJXzNXVW9KMS1XdThCTFFRWDdkNG9YSUU3TnJxNzFGU2piMEcxS3J2d3VqNnlhMlJNYlpvbnZ4Y3F6Sy1MMmxMOUV1VE8zZktjbGctUHZna1FWNmJoNTVxUG9RRXRHMVduSy01RlFzUEE3d3BheldmNzd1aXpDYzZ3?oc=5) |
| Clinical Trials Arena | Ultragenyx mulls fate of rare disease programme on Phase III flop | [Source Link](https://news.google.com/rss/articles/CBMipAFBVV95cUxPbkM4cUVEaVU5NWt2Z09UNWRvSEdzZUFvVGRMMnc5cGtBc21mREw2eFRmRlppOV92NzZGRnpFeTJTYUZkRzhOSnF0NnJtZ1Ixbzc1cGtpWXpGWjhVcXBoT0RzdEZKUmZIeFFWSWcyb1BjTjMwQ0tvQU1HLUdBNno5ZmdUUlBRdXVHLXAxU1VZM2tzbHZoN21GMnpnR2Zia1Q4b3I4Yg?oc=5) |
| MarketBeat | Ultragenyx Pharmaceutical (NASDAQ:RARE) Rating Lowered to "Equal Weight" at Wells Fargo & Company | [Source Link](https://news.google.com/rss/articles/CBMi6AFBVV95cUxQaUZKWFJacFhzczZNTldacFdJeGxQTzJoZUhsQm01Qm1mY05scDNhaDZMVm9sSmJ3bV9ndmVpTXdSRzJaUy1fV3dIOWtWUmZTRTZoZ1REM19uTkxDTWtUV213VHNWT2luMjloZldTVUNDSVdhbzhkYjNLcDIzUzZZeXY3RUNMbUZDZU1oTGZiZUFrZXFSNHhiaUVQUG1DUXVnbGRBWU90dll2X0VkMVJQblNSS1RrTEdqUVdReV9wT0oyYTNad0lWUFY0Q09FNVNzdHR6QWZpYW1TOUdoNkZGd20xRXJBRVpU?oc=5) |
| finance.yahoo.com | Ultragenyx Shares Fall After Phase 3 Aspire Study Misses Primary Endpoint | [Source Link](https://news.google.com/rss/articles/CBMilgFBVV95cUxQRWtvd3RUNHJWZmc5bVBIYzN5ZFlOWEY0MXd2a250QWJMYTdmT3BqUEhyWERTSXR2R19waHhibjdQYXRUOHFBek8tb0stOXZvQS1MTng5WVNIQWk0S25BOWs3SlJxV2xyMUU0WFlWSzJublZJa3oyUzVZRWQtaENYTC1RWUp6akduOVVFRHBmWDZuUFB1TVE?oc=5) |
| STAT | We’re reading about an Ultragenyx failure, RevMed for lung cancer, and more | [Source Link](https://news.google.com/rss/articles/CBMisgFBVV95cUxPb2xDb3h3b3gzWkRHam9yV0k0THB0aWpzYUVLeU1sdGlLYy1iWXBFY3B1Zkg1cDc1aFE1LVVQeVI0WC0wZTFTQ3Y3aG9WUnpOVGx0QXNyR1RKeFJqcHpPVEdnLURqOUVfc3NVcy1GR3JTdEQ1ZUNrMlUxM3N0SEZTaTgwdW5aTmVXX3F6VWplU1hoZkVwZW9md3EydmZJcXZMdGdFdUdkQmNqbk13M1NoSHln?oc=5) |
| Fierce Biotech | Ultragenyx fails phase 3 Angelman test, plots ‘significant expense reductions’ | [Source Link](https://news.google.com/rss/articles/CBMiswFBVV95cUxQTmJTbDZqWVJ3S1lRalJvY29La3N4SkptMVZCQlN2Zm5ubkxhbk5GNml2aDhqTWp6SGJDZlE4Qi0zaURCSmRGRjNjMWMtZzZpSjdRMkh4Z05NU0puMmdvQmlISmlZaUkzYkxYRnJGNzNQTWxqSnk5RjZ0bVRiZEFKQjNFTDZidHlsenFKQUUzeDg2TU5iRERLSFlGVE84MnFoWDFQdWlkNEpkczZ6QXhMa0xJbw?oc=5) |
| Barron's | Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline | [Source Link](https://news.google.com/rss/articles/CBMilAFBVV95cUxOSFlIY1hKMlExSDlIZFdGTFVPRkI4Q1ltd256YXF1My1nSkptOEJmbkpSd3FEOXJhYWJoUURrYjl0UlQyaFlHT3ZfR1hLbnlleTgyNmZzVWJpRGRYTm1RbHFXSGMtQnlvc0RHdGxUTzVQU0RvdEpCT1VMZnFuN0JqejY4bEFkVG1xZThoaG83WmswaVFW?oc=5) |
| FirstWord PHARMA | Ultragenyx's ASO fails in Angelman syndrome, triggering sell-off | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTFBFLTN0eFlzWVNxY0RCeVZKNVdMSUNfZmtGQ2FGa1RHbUVaX3pGcG9FVHFubTE5OTd0ZEEzbXpQRTU1dDRMRHNxRm5zVExBMXBqcVI0?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-09-03/is-ultragenyx-stock-a-buy-after-gtx-102-flop-analysts-point-to-commercial*